Last updated on November 2017

Allergan Migraine Ext: MD-04 (CRRI-Talbotton)


Brief description of study

Allergan Migraine Ext: MD-04 (CRRI-Talbotton)

Detailed Study Description

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura.

Clinical Study Identifier: TX15422

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »